{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:52:39Z","timestamp":1776487959957,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1124\/jpet.115.230201","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T02:23:32Z","timestamp":1447727012000},"page":"483-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells"],"prefix":"10.1016","volume":"356","author":[{"given":"David S.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunden","family":"Jinsmaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin J.","family":"Kopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehonatan","family":"Sharabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.230201_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10534-012-9525-y","article-title":"The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1","volume":"25","author":"Aguirre","year":"2012","journal-title":"Biometals"},{"key":"10.1124\/jpet.115.230201_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0021-9258(17)38262-5","article-title":"Tyrosine hydroxylase. Activation by protein phosphorylation and end product inhibition","volume":"253","author":"Ames","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.230201_bib3","doi-asserted-by":"crossref","first-page":"26978","DOI":"10.1074\/jbc.M111.249532","article-title":"Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone","volume":"286","author":"Anderson","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.230201_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1471-4159.1999.0731127.x","article-title":"Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson\u2019s disease","volume":"73","author":"Berman","year":"1999","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.115.230201_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","article-title":"Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine","volume":"115","author":"Burke","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1124\/jpet.115.230201_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","article-title":"3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis","volume":"989","author":"Burke","year":"2003","journal-title":"Brain Res"},{"issue":"5, Suppl 2","key":"10.1124\/jpet.115.230201_bib7","first-page":"50","article-title":"Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson\u2019s disease","volume":"41","author":"Carlsson","year":"1991","journal-title":"Neurology"},{"key":"10.1124\/jpet.115.230201_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01248762","article-title":"The role of intraneuronal amine levels in the feedback control of dopamine, noradrenaline and 5-hydroxytryptamine synthesis in rat brain","volume":"39","author":"Carlsson","year":"1976","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.115.230201_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(96)00530-4","article-title":"Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A","volume":"314","author":"Cho","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.115.230201_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.parkreldis.2010.04.008","article-title":"Trials of neuroprotective therapies for Parkinson\u2019s disease: problems and limitations","volume":"16","author":"de la Fuente-Fern\u00e1ndez","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.115.230201_bib11","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/clinchem\/32.11.2030","article-title":"Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase","volume":"32","author":"Eisenhofer","year":"1986","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.115.230201_bib12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0893-133X(95)00233-4","article-title":"Differential inhibition of neuronal and extraneuronal monoamine oxidase","volume":"15","author":"Eisenhofer","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.115.230201_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00426954","article-title":"Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the \u2018cheese effect\u2019","volume":"57","author":"Elsworth","year":"1978","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.115.230201_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0028-3908(91)90007-X","article-title":"Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig","volume":"30","author":"Fornstedt","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.115.230201_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0028-3908(86)90242-X","article-title":"Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species","volume":"25","author":"Fornstedt","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.115.230201_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/npp.2014.214","article-title":"Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain","volume":"40","author":"Fowler","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.115.230201_bib17","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1073\/pnas.90.16.7603","article-title":"Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector","volume":"90","author":"Geller","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.230201_bib18","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/aws055","article-title":"Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson\u2019s disease and other synucleinopathies","volume":"135","author":"Goldstein","year":"2012","journal-title":"Brain"},{"key":"10.1124\/jpet.115.230201_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pharmthera.2014.06.006","article-title":"Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders","volume":"144","author":"Goldstein","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.115.230201_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10286-007-0396-1","article-title":"Cardiac sympathetic denervation preceding motor signs in Parkinson disease","volume":"17","author":"Goldstein","year":"2007","journal-title":"Clin Auton Res"},{"key":"10.1124\/jpet.115.230201_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1471-4159.2012.07924.x","article-title":"Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson\u2019s disease","volume":"123","author":"Goldstein","year":"2012","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.115.230201_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jnc.12345","article-title":"Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson\u2019s disease","volume":"126","author":"Goldstein","year":"2013","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.115.230201_bib23","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1210\/jcem-64-4-856","article-title":"Neuronal source of plasma dihydroxyphenylalanine","volume":"64","author":"Goldstein","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.115.230201_bib24","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1471-4159.2008.05509.x","article-title":"Tyrosine hydroxylase activity is regulated by two distinct dopamine-binding sites","volume":"106","author":"Gordon","year":"2008","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.115.230201_bib25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/mds.23555","article-title":"Interpreting the results of Parkinson\u2019s disease clinical trials: time for a change","volume":"26","author":"Holford","year":"2011","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.115.230201_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0378-4347(93)E0430-X","article-title":"Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection","volume":"653","author":"Holmes","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1124\/jpet.115.230201_bib27","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jama.1964.03060390010002","article-title":"Monoamine oxidase inhibitors, tyramine, and cheese","volume":"188","author":"Horwitz","year":"1964","journal-title":"JAMA"},{"key":"10.1124\/jpet.115.230201_bib28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0028-3908(89)90169-X","article-title":"Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma","volume":"28","author":"Hovevey-Sion","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.115.230201_bib29","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1073\/pnas.68.10.2370","article-title":"Catecholamines and the hydroxylation of tyrosine in synaptosomes isolated from rat brain","volume":"68","author":"Karobath","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.230201_bib30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","article-title":"Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease. Pathophysiologic and clinical implications","volume":"318","author":"Kish","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.230201_bib31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0022-3565(25)11162-2","article-title":"Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation","volume":"261","author":"Kvetnansky","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.230201_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U","article-title":"Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde","volume":"60","author":"Lamensdorf","year":"2000","journal-title":"J Neurosci Res"},{"key":"10.1124\/jpet.115.230201_bib33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF00500085","article-title":"Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives","volume":"332","author":"Laschinski","year":"1986","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.115.230201_bib34","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI118492","article-title":"Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes","volume":"97","author":"Lenders","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.115.230201_bib35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1471-4159.1987.tb10009.x","article-title":"Monoamine oxidase in rat and bovine endocrine tissues","volume":"49","author":"Lenzen","year":"1987","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.115.230201_bib36","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.neuro.2009.07.006","article-title":"Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress","volume":"30","author":"Linsenbardt","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1124\/jpet.115.230201_bib37","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1517\/14656566.9.16.2881","article-title":"Orally disintegrating selegiline for the treatment of Parkinson\u2019s disease","volume":"9","author":"L\u00f6hle","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/jpet.115.230201_bib38","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1073\/pnas.1402134111","article-title":"Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo","volume":"111","author":"Lohr","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.230201_bib39","doi-asserted-by":"crossref","unstructured":"McCann H, Cartwright H, Halliday GM (2015) Neuropathology of \u03b1-synuclein propagation and braak hypothesis. Mov Disord 10.1002\/mds.26421.","DOI":"10.1002\/mds.26421"},{"key":"10.1124\/jpet.115.230201_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.neuro.2011.03.013","article-title":"Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite","volume":"32","author":"Mexas","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1124\/jpet.115.230201_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/exnr.1997.6662","article-title":"Neurotoxicity of endogenous cysteinylcatechols","volume":"148","author":"Montine","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.115.230201_bib42","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1523\/JNEUROSCI.0519-06.2006","article-title":"Alpha-synuclein overexpression increases cytosolic catecholamine concentration","volume":"26","author":"Mosharov","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.115.230201_bib43","doi-asserted-by":"crossref","first-page":"e15251","DOI":"10.1371\/journal.pone.0015251","article-title":"The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis","volume":"5","author":"Panneton","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/jpet.115.230201_bib44","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1523\/JNEUROSCI.5456-13.2014","article-title":"Is Parkinson\u2019s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum","volume":"34","author":"Pifl","year":"2014","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.115.230201_bib45","first-page":"323","article-title":"Influence of vesicular storage and monoamine oxidase activity on [11C]phenylephrine kinetics: studies in isolated rat heart","volume":"40","author":"Raffel","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1124\/jpet.115.230201_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1471-4159.2002.00808.x","article-title":"5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons","volume":"81","author":"Spencer","year":"2002","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.115.230201_bib47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1089\/hum.2004.15.1177","volume":"15","author":"Sun","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1124\/jpet.115.230201_bib48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1592\/phco.24.14.1295.43156","article-title":"Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor","volume":"24","author":"Th\u00e9bault","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1124\/jpet.115.230201_bib49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/syn.20408","article-title":"A small dopamine permeability of storage vesicle membranes and end product inhibition of tyrosine hydroxylase are sufficient to explain changes occurring in dopamine synthesis and storage after inhibition of neuron firing","volume":"61","author":"Wallace","year":"2007","journal-title":"Synapse"},{"key":"10.1124\/jpet.115.230201_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0161-813X(03)00103-7","article-title":"Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation","volume":"25","author":"Youdim","year":"2004","journal-title":"Neurotoxicology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.230201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:42:19Z","timestamp":1739994139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524192440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0022356524192440"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.230201","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.230201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}